Charles River Laboratories International Inc.
CRL
Get informed when a big investor buys or sells
+ FollowMarket Cap$14.22B
Close$
$250.69
10.2% downsideCharles River Laboratories International Target Price Details
Target Price by Analysts
10.2% downsideCharles River Laboratories International Target Price Details$70.2674.8% downside
Current Fair Value
74.8% downsideOvervalued by 74.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $14.22 Billion |
|---|---|
| Enterprise Value | $17.26 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.91 |
| Beta | 1.38 |
| Outstanding Shares | 48,486,000 |
Return
| Return on Equity | -8.40% |
|---|---|
| Return on Assets | -3.17% |
| Return on Invested Capital | 6.82% |
Valuation & Multiples
| P/E Ratio | -60.99 |
|---|---|
| PEG | 59.31 |
| Price to Sales | 3.4 |
| Price to Book Ratio | 4.81 |
| Enterprise Value to Revenue | 4.32 |
| Enterprise Value to EBIT | 39.56 |
| Enterprise Value to Net Income | -73 |
| Total Debt to Enterprise | 0.19 |
| Debt to Equity | 1.14 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$2.74
Average shareholder expectationRevenue Estimate
$977.20 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$2.97
Average shareholder expectationRevenue Estimate
$958.47 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5452▼ 18.05% |
|---|---|
| Total Calls | 241,200▲ 5.14% |
| Total Puts | 131,500▼ 21.01% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 116.86%▲ 0.80% |
|---|---|
| Total Invested | $12.94B▲ 31.23% |
| Investors Holding | 574▲ 3.00% |
ESG Score
No data
About Charles River Laboratories International Inc.
17,000 employees
CEO: James Foster Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our...